Compare AbbVie Inc (ABBV) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.58. The key difference: AbbVie Inc pays a 2.79% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | QDTY | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $46.71 |
52-Week Low | $197.38 | $36.57 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
QDTY trades at $39.78, up 1.02% today, with a bearish technical signal from moving averages and mixed oscillators. The stock shows consistent weekly dividend distributions, but key valuation and profitability ratios are unavailable. Recent news highlights ongoing dividend announcements from YieldMax ETFs, indicating a focus on income generation.
The outlook is cautious due to bearish technicals and lack of fundamental data; risks include market volatility and dependency on dividend strategy. Investors should seek updated financials for a clearer assessment of growth potential and sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
